At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 265 enrolled
Drug / intervention
Herpes Zoster vaccine GSK1437173A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Observer-blind Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults 18 Years of Age or Older With Renal Transplant
In Brief
A Phase 3 clinical trial evaluating Herpes Zoster vaccine GSK1437173A and Placebo for Herpes Zoster. Completed, enrolled 265 participants across 34 sites in 9 countries.
Detailed Summary
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine administered on a 0- and 1- to 2-months schedule in adults 18 years of age or older who are receiving chronic immunosuppressive therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster
CountriesBelgium, Canada, Czechia, Finland, Italy, Panama, South Korea, Spain, Taiwan
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 2014
Enrollment StartMar 2014
Primary CompletionMay 2016
Study CompletionApr 2017
TodayJul 2026
First PostedFeb 10, 2014
Enrollment StartMar 20, 2014
Primary CompletionMay 11, 2016
Study CompletionApr 13, 2017
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 12.4 years ago
Interventions
Herpes Zoster vaccine GSK1437173Abiological
2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
Placebodrug
2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.